Next Article in Journal
Next Generation Sequencing As an Aid to Diagnosis and Treatment of an Unusual Pediatric Brain Cancer
Next Article in Special Issue
Surveillance Recommendations in Reducing Risk of and Optimally Managing Breast Cancer-Related Lymphedema
Previous Article in Journal
A Systematic Review and Meta-Analysis of Mobile Devices and Weight Loss with an Intervention Content Analysis
Previous Article in Special Issue
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
Open AccessReview

Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design

1
Department of Medicine, Albert Einstein Medical Center, 5501 Old York Street, Philadelphia, PA 19141, USA
2
Department of Thoracic Head and Neck, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2014, 4(3), 386-401; https://doi.org/10.3390/jpm4030386
Received: 26 March 2014 / Revised: 10 June 2014 / Accepted: 13 June 2014 / Published: 30 June 2014
(This article belongs to the Special Issue Personalized Cancer Therapy)
The approval of EGFR and ALK directed tyrosine kinase inhibitors materialized the concept of tailoring therapy on the basis of specific biomarkers for treating patients with NSCLC. Research for other biologics, although demonstrating clinical benefit, has been less successful so far for producing biomarkers that predict response. Blocking angiogenesis is the prototype for the agents that belong in the latter group that target specific molecules, yet they are currently approved for relatively unselected groups of patients. In order to meet the goal of personalizing care in the various settings of NSCLC, a wealth of biologics and compounds are currently being tested in clinical trials in different phases of clinical development. In a subset of the relevant studies, a biomarker perspective is appreciated. This review summarizes the clinical rationale of the major ongoing phase II and III NSCLC studies that employ targeting specific molecules with novel agents, as well as innovative strategies, and includes a comparative discussion of the different designs. View Full-Text
Keywords: targeted therapies; selumetinib; NSCLC; onartuzumab; MET; PI3K; MEK; ALK; erlotinib; afatinib; crizotinib targeted therapies; selumetinib; NSCLC; onartuzumab; MET; PI3K; MEK; ALK; erlotinib; afatinib; crizotinib
MDPI and ACS Style

Dimou, A.; Papadimitrakopoulou, V. Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. J. Pers. Med. 2014, 4, 386-401.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop